nach oben

Clinical Pharmacokinetics

Erschienen in:

01.02.2006 | Correspondence

The Authors’ Reply

verfasst von: Alwin D. R. Huitema, Jos H. Beijnen

Erschienen in: Clinical Pharmacokinetics | Ausgabe 2/2006

Einloggen, um Zugang zu erhalten

Excerpt

We thank Drs Back, Owen and Khoo for their interest in our recent paper Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1 Infected Individuals.[1] …

Kappelhoff BS, Huitema ADR, Yalvac Z, et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet 2005; 44(8): 849–61PubMedCrossRef

Crommentuyn KML, Kappelhoff BS, Mulder JW, et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1 infected patients. Br J Clin Pharmacol 2005; 60: 378–89PubMedCrossRef

Kappelhoff BS, Huitema ADR, Sankatsing SU, et al. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1 infected patients. Br J Clin Pharmacol 2005; 60: 276–86PubMedCrossRef

Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Swiss HIV cohort study. Pharmacogenet Genomics 2005; 15: 1–5PubMedCrossRef

Haas DW. Will pharmacogenomic discoveries improve HIV therapeutics?. Topics in HIV Medicine 2005; 13: 90–5PubMed

Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Swiss HIV Cohort Study. Lancet 2002; 359: 30–6PubMedCrossRef

Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391–400PubMed

Hasse B, Gunthard HF, Bleiber G, et al. Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis 2005; 40: E22–3PubMedCrossRef

Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005; 40: 1358–61PubMedCrossRef

Titel: The Authors’ Reply
verfasst von: Alwin D. R. Huitema
Jos H. Beijnen
Publikationsdatum: 01.02.2006
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 2/2006
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200645020-00007

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2006

Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals

Fosamprenavir

Pharmacokinetic Interaction between Levofloxacin and Ciclosporin or Tacrolimus in Kidney Transplant Recipients

Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease

Pharmacokinetics of Darbepoetin Alfa after Intravenous or Subcutaneous Administration in Patients with Non-myeloid Malignancies Undergoing Chemotherapy

Role of Mechanistically-Based Pharmacokinetic/Pharmacodynamic Models in Drug Development